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Peroxisome proliferator-activated receptors are expressed in many tissues, including adipocytes, hepatocytes,
muscles and endothelial cells; however, the affinity depends on the isoform of PPAR, and different distribution and
expression profiles, which ultimately lead to different clinical outcomes. Because they play an important role in lipid
and glucose homeostasis, they are called lipid and insulin sensors. Their actions are limited to specific tissue types
and thus, reveal a characteristic influence on target cells. PPARα mainly influences fatty acid metabolism and its
activation lowers lipid levels, while PPARγ is mostly involved in the regulation of the adipogenesis, energy balance,
and lipid biosynthesis. PPARβ/δ participates in fatty acid oxidation, mostly in skeletal and cardiac muscles, but it also
regulates blood glucose and cholesterol levels. Many natural and synthetic ligands influence the expression of these
receptors. Synthetic ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in
diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists). New generation drugs - PPARα/γ dual agonists - reveal
hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action while the overexpression of
PPARβ/δ prevents the development of obesity and reduces lipid accumulation in cardiac cells, even during a
high-fat diet. Precise data on the expression and function of natural PPAR agonists on glucose and lipid metabolism
are still missing, mostly because the same ligand influences several receptors and a number of reports have
provided conflicting results. To date, we know that PPARs have the capability to accommodate and bind a
variety of natural and synthetic lipophilic acids, such as essential fatty acids, eicosanoids, phytanic acid and
palmitoylethanolamide. A current understanding of the effects of PPARs, their molecular mechanisms and the role
of these receptors in nutrition and therapeutic treatment are delineated in this paper.Introduction
Peroxisome proliferator-activated receptors are ligand-
activated transcription factors that regulate genes import-
ant in cell differentiation and various metabolic processes,
especially lipid and glucose homeostasis. In molecular
terms, PPARs represent a family of ligand-activated nu-
clear hormone receptors (NRs) belonging to the steroid
receptor superfamily [1,2] (Figure 1). Examples of NRs in-
clude the receptors for thyroid hormones, retinoids, 1,25-
dihydroxy-vitamin D3, steroid hormone receptors and a
variety of other ligands. After interaction with the specific
ligands, nuclear receptors are translocated to the nucleus,Correspondence: bgrygiel@ump.edu.pl
Department of Bromatology and Human Nutrition, University of Medical
Sciences, Poznan, Poland
© 2014 Grygiel-Górniak; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
waiver (http://creativecommons.org/publicdom
stated.where they change their structure and regulate gene tran-
scription [3-5].
PPAR structure and function
The three-dimensional structure of PPARs consists of a
DNA binding domain in the N-terminus and a ligand
binding domain (LBD) in the C-terminus. After inter-
action with agonists, PPARs are translocated to the
nucleus and heterodimerize with another nuclear recep-
tor - the retinoid X receptor (RXR) (Figure 2). The RXR
forms a heterodimer with a number of other receptors
(e.g., vitamin D or thyroid hormones). The specific DNA
regions of target genes that bind with PPARs are termed
peroxisome proliferator hormone response elements
(PPREs) [1]. The PPREs are found in the promoters of
PPAR responsive genes, such as the fatty acid-bindingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Figure 1 Superfamily of nuclear hormone receptors.
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transcription of various genes involved in diverse physio-
logical and pathophysiological processes.
The function of PPARs is modified by a number of co-
activators and corepressors, the presence of which can
either stimulate or inhibit receptor function, respectively
[6]. Ligands that activate PPARγ-RXR cause an exchange
of co-repressors for co-activators [7,8]. Human cells are
characterized by a different availability of cofactors that
depends on the type of cell and the association of spe-
cific cofactors to other genes [7,9,10].Types of PPARs and their tissue expression
The family of peroxisome proliferation-activated recep-
tors comprises three isoforms: PPARα, PPARβ/δ and
PPARγ [1]. These three isotypes differ from each other
in terms of their tissue distributions, ligand specificities
and physiological roles. Each of them either activates or
suppresses different genes with only partial overlap in
activity (Figure 3) [5]. All isoforms participate in lipid
homeostasis and glucose regulation (energy balance),
and, until recently, their actions were thought to be lim-
ited to specific tissue types (Figure 4) [5,11]. PPARα is
highly expressed in metabolically active tissues, such as
liver, heart, skeletal muscle, intestinal mucosa and brown
adipose tissue. This receptor is implicated in fatty acid
metabolism and its activation lowers lipid levels [12-15].
PPARγ is expressed in white and brown adipose tissue,
the large intestine and spleen. However, its expression is
highest in adipocytes and it plays a key role in the




Figure 2 Mechanism of gene transcription by PPARs.biosynthesis [14,16-18]. This receptor also participates in
lipoprotein metabolism and insulin sensitivity.
The least known isoform is PPARβ/δ, which has not
been so intensely studied as PPARα and PPARγ. PPARβ/δ
is expressed ubiquitously in virtually all tissues; however, it
is particularly abundant in the liver, intestine, kidney, ab-
dominal adipose tissue, and skeletal muscle, all of which
are involved in lipid metabolism. It participates in fatty
acid oxidation, mainly in skeletal and cardiac muscles, reg-
ulates blood cholesterol concentrations and glucose levels
[1,13,19,20].
In conclusion, PPARα and PPARβ/δ mainly facilitate
energy combustion, whereas PPARγ contributes to en-
ergy storage by enhancing adipogenesis [21].
PPAR ligands
Many natural and synthetic agonists of PPARs are used in
the treatment of glucose and lipid disorders. PPARs per-
form different activities, mainly via endogenous ligands
produced in the metabolic pathways of fatty acids; and
therefore, they are called lipid sensors. PPAR agonists have
different properties and specificities for individual PPAR
receptors, different absorption/distribution profiles, and
distinctive gene expression profiles, which ultimately lead
to different clinical outcomes [1,5,17,22,23].
The characteristic feature of the PPAR ligand binding
cavity is its size, which is 3–4 times larger than that of
the other nuclear receptors. Thus, PPARs have the cap-
ability to accommodate and bind a variety of natural and
synthetic lipophilic acids, such as essential fatty acids
(EFA) (Figure 5). These acids act as PPAR agonists that
transcript the genes involved in glucose and lipidDNA 
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Figure 3 PPARs and their gene targets.
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acid and eicosapentaenoic acid used in the prevention
and treatment of cardiovascular and metabolic diseases
[25]. Not only EFA but also eicosanoids are natural li-
gands of PPARs – e.g. leukotriene B4 stimulates PPARα,
and prostaglandin PGJ2 activates PPARγ [22]. However,
both EFA and eicosanoids are required in relatively high
concentrations (approximately 100 μM) for PPAR activa-
tion [24]. Also, synthetic ligands are widely used in clin-
ical practice – for example, fibrates (PPARα ligands) are
recommended in the dyslipidemic state (hypertriglyc-
eridemia) and thiazolidinediones (PPARγ agonists) are
used in the treatment of diabetes mellitus [26-29].
Functional role of PPARα
As mentioned above, PPARα is expressed mainly in tis-
sues with a high capacity for fatty acid oxidation, e.g. the
liver, heart, and skeletal muscle. It also plays a role inMain tissue expression:
tissues exhibiting high 
carbolic rates of fatty acids 




intestinal mucosa, and 








Figure 4 Expression of PPARs in specific tissues.glucose homeostasis and insulin resistance development
(Figure 6) [29]. Natural or pharmacological ligands (fatty
acids and fibrates, respectively) primarily control the ex-
pression of genes involved in lipid metabolism. If the
concentration of fatty acids increases, PPARα is activated
and uptakes oxidized forms of these acids [30,31]. Oxi-
dation of fatty acids is mainly present in the liver and it
prevents steatosis in the case of starvation/fasting. Dur-
ing the influx of fatty acids, transcription of PPARα-
regulated genes is stimulated and the oxidation systems
(microsomal omega-oxidation system, and mitochondrial
and peroxisomal beta-oxidation) are activated (Figure 7)
[21,32]. This activation and increased PPARα sensing in
the liver result in increased energy burning and reduced
fat storage. Conversely, ineffective PPARα sensing or de-
creased fatty acid oxidation causes a reduction in energy
burning that results in hepatic steatosis and steatohepa-
titis (especially during overnight or prolonged fasting)n: 
ver the 
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Figure 5 Natural and synthetic ligands of PPAR.
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tems is caused by genetic or toxic factors (including
drug related ones), and metabolic disturbances. In ani-
mal models, inefficient PPARα sensing (characteristic for
PPARα_/_ mice) enables the oxidation of the influxed
fatty acids and leads to severe hepatic steatosis develop-
ment. Administration of PPARα agonists prevents these
processes and even reverses hepatic fibrosis (in animal
models) [34]. Thus, PPARα functions as a lipid sensorFigure 6 The role of PPARs (↑ - increase, ↓ - decrease).and it controls energy combustion. It also plays also a
prominent role in the pathogenesis of fatty liver disease
(FLD) and ligands of this receptor might be effective in
the reduction of hepatic staetosis by increasing energy
utilization [32,33].
Natural agonists of PPARα
The natural ligands of PPARα are omega-3 fatty acids.





































and reduced fat 
storage
Figure 7 Consequence of PPARα activation.
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molecule of docosahexaenoic acid – DHA and eicosa-
pentaenoic acid – EPA), a linker region (their long chains),
and a hydrophobic tail [16]. Because omega-3 fatty acids
are highly polyunsaturated, they readily undergo oxidation
and stimulate PPARs. Sethi et al. proved that not only na-
tive EPA but also oxidized EPA modestly activates PPARα.
Moreover, oxidized EPA, much more than native EPA,
stimulates this receptor in endothelial cells. Therefore, it is
suspected that oxidation of the omega-3 fatty acids con-
verts them into a stronger PPARα agonist [30]. Similarly,
oxidation of LDL transforms them into potent stimulators
of PPARα in endothelial cells [31]. Thus, the possibility of
lipid oxidation may be one of the first steps involved in
the generation of efficient PPARα agonists.
In addition to PPAR activation, EPA and DHA have
many beneficial health effects which are not characteristic
for PPAR ligands. They reduce the risk of coronary heart
disease, hypertension, primary heart attack, rheumatoid
arthritis and play an important role in the development of
attention-deficit/hyperactivity disorder [25]. These benefi-
cial effects are not observed with other typical PPARs li-
gands; however, EPA and DHA do not show a number of
PPAR effects, such as decreasing insulin resistance, that
probably occur due to dissociation between n-3 polyunsat-
urated fatty acids and lipid metabolism in the hypergly-
cemic state [35].
Omega-3 fatty acids also reveal an anti-inflammatory
effect that results from the inhibition of their own oxida-
tion caused by activated NF-κB in a PPARα-dependent
pathway [14,16]. In addition, PPARα mediates the anti-
inflammatory actions of palmitoylethanolamide, the
naturally occurring amide of palmitic acid and etha-
nolamine [15].
Synthetic agonists of PPARα
Synthetic PPARα ligands such as fibrates (e.g. clofibrate,
fenofibrate, and bezafibrate) decrease the triglyceride-richlipoproteins in serum through an increase in the gene ex-
pression involved in fatty acid-β-oxidation and a decrease
in apolipoprotein C-III gene expression [26,29]. They are
widely used in the pharmacological treatment of hypertri-
glyceridemia. After activation by fibrates, PPARα receptors
connect with the 9-cis retinoic acid receptor and then
bind to peroxisome proliferator response elements.
Fibrates not only reveal a triglyceride-lowering effect, but
also increase HDL cholesterol (partly by increasing apoli-
poprotein A-I and A-II gene expression). Their activity re-
sults in decreasing systemic availability of fatty acids and a
lowering of fatty acid uptake in muscles. They also in-
crease insulin sensitization and reduce plasma glucose
levels [12,26,29]. In consequence, they may slow arterio-
sclerosis progression and reduce cardiovascular events
[36]. However, two large-scale studies into fibrates (the
FIELDstudy and the ACCORDlipid arm) in patients with
diabetes did not show any reduction in fatal cardiovascular
incidences or non-fatal myocardial infarction and stroke
compared with simvastatin alone [37,38]. It must also be
underlined that fibrate intake may cause an increase in
serum creatinine levels (via a decrease in tubular secretion,
reduced clearance and possibly increased production of
creatinine) [39-41]. However, long-term studies have
shown a slowing of the decline in renal function [37-39].
Active metabolites of fibrates, such as clofibric acid
and fenofibric acid, are dual activators of PPARα and
PPARγ, with about a 10-fold selectivity for PPARγ. The
effect of bezafibrate, another compound from this group,
is wider because it activates all 3 PPAR subtypes (α, γ
and δ) at comparable doses to other fibrates [1,5].
Therefore, bezafibrate is considered a panagonist for all
3 PPAR isoforms with the potential to directly improve
insulin sensitization via PPARγ activation.
Functional role of PPARβ/δ
PPARβ/δ (referred to also as PPARδ, PPARβ, hNUC1 or
FAAR) plays a key role in lipid and cholesterol metabolism.
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profiles and reducing adiposity, which in consequence
prevents obesity development [19,42]. In animals, PPARβ/
δ serves as a regulator of fat consumption. PPARβ/δ-
deficient mice challenged with a high-fat diet showed
reduced energy uncoupling and were prone to obesity,
whereas PPARβ/δ activation led to resistance to nutrition-
ally (induced by high-fat diet) or genetically triggered obes-
ity (in genetically modified mice) [19].
Decreased PPARβ/δ expression is also observed in car-
diac muscle during the hyperglycemic state in diabetes
mellitus [43,44]. Conversely, overexpression of this re-
ceptor in cardiac cells diminishes lipid accumulation in
the presence of a high fat diet, and increases glucose
metabolism. In consequence, the heart is protected against
ischemia-reperfusion injury, suggesting that activation
of this receptor might be useful in diabetic cardiomy-
opathy [45].
Also beneficial is PPARβ/δ activation in adipocytes
and skeletal muscles that results in fatty acid oxidation
and utilization (studies in vitro) [19]. Thus, PPARβ/δ
might be considered a potential target in the treatment
of obesity and obesity related disorders. This receptor is
also a mediator of embryo implantation and cancer de-
velopment [42,46]. Its high expression in the large intes-
tine has been implicated in the development of colon
cancer [11,47]. In this process, PPARβ/δ was stimulated
by arachidonic acid, which resulted in the upregulation
of cyclooxygenase (COX)-2 and the overproduction of
prostaglandin (PG)E2 – an activator of colon cancer
cells. Similarly, activation of PPARβ/δ also stimulated
the cell line proliferation of human breast and prostate
cancer [20].
Agonists of PPARβ/δ
Dual agonists of PPARβ/δ improve insulin sensitivity in
both murine models and in humans. Thus, they might
be considered a potential target in the treatment of
obesity and obesity associated disorders. Only bezafi-
brate, a traditional PPARα agonist, seems to be a safe
pan-agonist for all PPAR isotypes, but it has relatively
low potency and low affinity for PPARβ/δ [48].
Clinical and nutritional role of PPARγ
PPARγ has attracted significant scientific and clinical
interest because of its role in macronutrient metabolism.
It is a target of the synthetic insulin sensitizers – thiazo-
lidinediones - used in the treatment of type 2 diabetes
mellitus. This receptor is abundantly expressed in adi-
pose tissue where it plays a central role in adipogenesis
and appears to be primarily involved in the regulation of
lipid metabolism. Because the PPARγ gene has separate
promoters and 5’exons, it results in three mRNAs:
PPARγ1, PPARγ2, and PPARγ3. Proteins produced fromPPARγ1 and PPARγ3 mRNAs are identical, whereas the
product of PPARγ2 contains an additional NH2-terminal
region composed of 30 amino acids. All PPARγ isoforms
play an important role in adipocyte differentiation and
glucose metabolism; however, their expression is dif-
ferent. The PPARγ1 isoform is expressed in nearly all
cells, while PPARγ2 is limited mainly to adipose tissue.
Nevertheless, PPARγ2 is a more potent transcription acti-
vator [8].
Both forms of PPARγ1 and PPARγ2 are essential for
the development of adipose tissue and the control of in-
sulin sensitivity. However, PPARγ2 is the isoform regu-
lated in response to nutrient intake and obesity [9,10].
The study of Medina-Gomez et al. based on an animal
model proved that removing PPARγ2 from genetically
obese POKO mice decreases the fat accumulation in adi-
pocytes compared to normal obese mice on the same
diet. This study showed that the PPARγ2 isoform pre-
vents lipotoxicity in different mechanisms including pro-
motion of adipose tissue expansion, the augmentation of
lipid-buffering capacity in peripheral organs (liver,
muscle, and beta cells of pancreas), and the proliferative
response of β-cells to insulin resistance [18].
Adipose PPARγ protects non-adipose tissues against
excessive lipid overload and maintains normal organ
function (liver, skeletal muscle). Activated PPARγ in adi-
pocytes guarantees a balanced and adequate secretion of
adipocytokines (adiponectin and leptin) that are media-
tors of insulin action in peripheral tissues. In conse-
quence, the insulin sensitivity of the whole body is
maintained [49]. Apart from this adipogenetic activity,
PPARγ is also important in lipid metabolism, and it reg-
ulates the genes participating in the release, transport,
and storage of fatty acids such as lipoprotein lipase
(LPL) and the fatty acid transporter CD36 [9,17,18].
PPARγ is the potent function modulator not only
found in adipose tissue but also in endothelial cells
and vascular smooth muscle cells. In endothelial cells
it regulates targets relevant to inflammation and ath-
erosclerosis [50].
Despite controlling lipid metabolism, PPARγ also partic-
ipates in the regulation of cancer development. Their ago-
nists inhibit or promote cancer growth depending on
cellular conditions and the stimulated signaling pathway
(anti-proliferative and apoptotic) [8,31]. They influence
tumor-associated macrophages and tumor vasculature
and significantly attenuate tumor progression [23]. These
data suggested that PPARγ ligands may become new con-
venient therapeutic modifiers targeting simultaneously tu-
mors and their microenvironment [51].
Natural agonists of PPARγ
The selective PPARγ modulators are often called SPARMs
by analogy to selective estrogen receptor modulators
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cellular context and on different receptor conformations,
resulting in diverse gene interactions [52].
Selected fatty acids are considered natural modulators
of PPARγ; however, their connection with the receptor
does not always lead to PPAR activation and target gene
transcription. Activation of PPARγ by natural ligands
such as PUFAs (mainly docosahexaenoic acid and ei-
cosapentaenoic acid) results in a functional response in
the tumor cells. Many studies have provided evidence
that DHA inhibits the tumor development through acti-
vation of PPARγ (e.g. the growth of human lung cancer
cells) [53]. If DHA is delivered to breast cancer cells by
albumin or by enriched LDL with n-3 PUFAs, it inhibits
the proliferation of these cells and stimulates their apop-
tosis [54-56]. Syndecan-1 (the heparan sulfate proteogly-
can) - the activating factor of apoptosis - participates in
this process. After the stimulation of PPARγ by DHA,
the transcriptional upregulation of the syndecan-1 target
gene is present [56]. In animal studies long-chain mono-
unsaturated fatty acids (LC-MUFAs) with chain lengths
longer than 18 (i.e., C20:1 and C22:1 isomers combined)
may ameliorate obesity-related metabolic dysfunction
through increased expression of PPARγ and decreased
inflammatory marker expression in white adipose tissue
[57]. In in vitro studies, activation of PPARα and
PPARβ/δ in human cell lines of breast cancer stimulated
cell proliferation [58,59], whereas ligands for PPARγ
inhibited this process [20].
Apart from polyunsaturated fatty acids, phytanic acid
is also a natural PPARγ agonist in the human diet that
reveals a similar activity to omega-3 PUFA and increases
glucose uptake and insulin sensitivity; however, with less
capacity to differentiate adipocytes [60].
PPARγ pharmacological agonists
PPARγ is a regulator of lipid and glucose metabolism
and therefore its synthetic ligands such as glitazones –
the derivatives of thiazolidinediones (e.g., troglitazone,
rosiglitazone and pioglitazone) - improve insulin and
glucose parameters and increase whole body insulin sen-
sitivity. Therefore, they are called insulin-sensitizing
medications used in the treatment of diabetes [61]. They
indirectly increase insulin-stimulated glucose uptake in
adipocytes, hepatocytes and skeletal muscle cells [62,63].
The effects of pharmacological PPARγ activation by thia-
zolidinediones have been attributed, at least in part, to
decreased free fatty acid (FFA) levels and increased lipid
storage in adipose tissue, in which it is most highly
expressed. In consequence, lipotoxicity in the muscles
and liver is reduced. PPARγ agonists also have the ability
to redistribute fat from visceral to subcutaneous depots
and increase adiponectin and reduce tissue necrosis fac-
tors [63,64]. Moreover, rosiglitazone and pioglitazone areused in the treatment of patients with type 2 diabetes be-
cause they decrease hepatic glucose production and pro-
long pancreatic β-cell function by preventing apoptosis of
β-cells [62,63]. They reduce fasting plasma glucose and
glycated hemoglobin A1c (pioglitazone 15–45 mg/day,
rosiglitazone 2–6 mg/twice a day) [65-67]. However, the
influence of both thiazolidinediones on cardiovascular
outcomes in patients with diabetes mellitus is different.
The positive effect of pioglitazone was demonstrated in a
PROactive study revealing 16% reduced cardiovascular
complications in the main secondary endpoint (a compos-
ite of all-cause-mortality, non-fatal myocardial infarction
and stroke) compared with placebo treatment [68]. Con-
versely, rosiglitazone was associated with significant in-
creases in myocardial infarction and death from
cardiovascular causes after only relatively short-term ex-
posure [69] and the European Medicines Agency with-
drew approval of this medication in 2010 due to these
cardiovascular safety concerns [64]. The differences be-
tween thiazolidinediones are probably caused by their di-
verse effects on lipid sub-fractions [63]. Pioglitazone
increases HDL cholesterol and decreases triglycerides and
fasting plasma free fatty acids (without any influence on
total cholesterol and LDL cholesterol) [64,70,71]. Rosigli-
tazone significantly augments HDL levels [64,70,71], total
cholesterol and the LDL fraction [71].
In diabetes mellitus, long-term activation of PPARγ by
thiazolidinediones not only reduces glycaemia and insu-
linemia but also attenuates vascular dysfunction [72].
PPARγ is expressed in vessels, specifically in vascular
smooth muscle cells and endothelium. Recent studies
suggest that activators of PPARγ not only modify meta-
bolic disturbances but also protect vascular function in
diabetes [72]. Using an animal model, Bagi et al. proved
that short-term treatment of type 2 diabetic mice with
rosiglitazone augmented NO-mediated flow-dependent
dilations of coronary arterioles by reducing vascular
superoxide production via a favorable alteration of oxi-
dant/antioxidant enzyme activities [73]. PPARγ agonists
also lower blood pressure and decrease circulating PAI-1
and CRP levels in patients with diabetes [27,28].
Apart from these positive effects, activation of PPARγ
by glitazones attenuates systemic inflammation [3,4] and
reduces tumor growth and angiogenesis. PPARγ activa-
tion by agonist RS5444 may inhibit anaplastic thyroid
cancer growth [74]. Only troglitazone revealed tumor-
promoting and pro-angiogenic properties – it promoted
hepatic carcinogenesis and liposarcomas, and thus this
agonist was rejected from the treatment [72,75].
Despite many beneficial features of glitazones (meta-
bolic and anti-arteriosclerotic activity), they also exhibit
side effects, such as weight gain, edema, bone fractures,
heart failure and increased risk of myocardial infarctions,
which have limited the use of these drugs in diabetic
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lective PPARγ modulators are currently in development
(such as S26948 [77] and INT131 [78]) and these should
stimulate glucose metabolic pathways and minimize the
side effects of full PPAR-γ agonists.
PPARα/γ dual agonists
The synthesis of new drug generation - PPARα/γ dual ago-
nists - connecting positive influences on both lipid and glu-
cose metabolism has been recently developed as a
response to the treatment challenge of co-existing type 2
diabetes mellitus with dyslipidemia. These double agonists
not only have anti-diabetic capacity but also reduce arterio-
sclerosis development. They also exhibit anti-inflammatory
and anticoagulant action, improve endothelial function, de-
crease plasma free fatty acids and lower blood pressure re-
vealing beneficial effects on the vasculature. However,
recent studies show that PPARα/γ dual agonists, similar to
glitazones, exhibit the same side effects; for example,
weight gain and edema [48,79]. None of them may be
safely used in clinical treatment because of the increased
risk of bladder cancer and hyperplasia (ragaglitazar and
naveglitazar) or [80], renal dysfunction (tesaglitazar) [81]
and increased cardiovascular risk (muraglitazar) [82]. A re-
cent study (currently in phase III trials) of aleglitazar de-
creased HbA1c and revealed beneficial effects on lipid
profiles reducing triglyceride and LDL, and increasing
HDL cholesterol. It changes the atherogenic small dense
LDL particles into larger LDL molecules [108] and in con-
sequence reduces inflammatory/cardiovascular risk [83].
This thiazolidinedione with a balanced affinity for both α
and γ receptor subtypes is very promising; however, further
studies are needed.
Conclusions
Considering the wide range of actions on glucose, lipid
metabolism and cell proliferation/apoptosis, PPARs and
their modulators are suggested for the treatment of meta-
bolic disorders such as hyperglycaemia, dyslipidemia and
atherosclerosis. The prevention and treatment of both
lipid and glucose profile disorders should consider the po-
tency and affinity of selective PPARs and their potential
cancerogenic influences. Therefore, natural compounds
and their close derivatives are being targeted as future
drugs against metabolic diseases. Even though early pre-
clinical data are very promising, it is necessary to evaluate
the clinical properties of new PPAR agonists and their in-
fluence on patient health.
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